Radotinib (SupectTM) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.